Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
34 hedge funds and large institutions have $16.4M invested in Cellular Biomedicine Group, Inc. in 2017 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 14 reducing their positions, and 2 closing their positions.
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
11% less funds holding
Funds holding: 38 → 34 (-4)
14% less capital invested
Capital invested by funds: $19.1M → $16.4M (-$2.69M)
21% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$7.31M |
| 2 |
SG Americas Securities
New York
|
+$234K |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.3K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.5K |
| 5 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$11.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$322K |
| 2 |
Morgan Stanley
New York
|
-$236K |
| 3 |
Citigroup
New York
|
-$148K |
| 4 |
Millennium Management
New York
|
-$145K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
-$60K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
UBS Group
Zurich,
Switzerland
| $16K | -$26.1K | -2,145 | -62% |
|
|
AIP
27
Ameritas Investment Partners
Lincoln,
Nebraska
| $9K | +$9.22K | +759 | New |
|
|
MAM
28
Meeder Asset Management
Dublin,
Ohio
| $7K | +$3.22K | +265 | +75% |
|
29
Royal Bank of Canada
Toronto,
Ontario, Canada
| $6K | -$2.37K | -195 | -26% |
|
30
Creative Planning
Overland Park,
Kansas
| $4K | – | – | – |
|
31
BNP Paribas Financial Markets
Paris,
France
| $767 | -$2.03K | -167 | -72% |
|
|
32
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$322K | -24,584 | Closed |
|
|
33
Citigroup
New York
| – | -$148K | -12,206 | -100% |
|
|
34
Russell Investments Group
London,
United Kingdom
| – | -$60K | -4,504 | Closed |
|
35
Barclays
London,
United Kingdom
| – | -$1.08K | -89 | -61% |
|
CBMG Hedge Fund Activity: Q1 2017 in Review
34 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q1 2017, worth a combined $16.4M — down 14% from $19.1M a quarter earlier.
Fund positioning in CBMG was balanced in Q1 2017: 2 funds opened new positions, 2 closed out, 11 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $7.31M. The largest seller was Susquehanna International Group, exiting entirely with an estimated $322K sold.
- 34 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q1 2017, down from 38 in Q4 2016.
- Funds reported $16.4M of Cellular Biomedicine Group, Inc. stock for Q1 2017, down 14% quarter-over-quarter.
- 2 funds opened new Cellular Biomedicine Group, Inc. positions in Q1 2017 and 2 closed out, a net change of 0 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q1 2017 was BlackRock, an estimated $7.31M added.
- The largest Cellular Biomedicine Group, Inc. seller in Q1 2017 was Susquehanna International Group, an estimated $322K sold.
Based on aggregated 13F filings for Q1 2017.